Ipamorelin
Ipamorelin is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.
Ipamorelin significantly increases plasma growth hormone levels in both animals and humans. In addition, ipamorelin stimulates body weight gain in animals. Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone, luteinizing hormone, or thyroid-stimulating hormone levels. However, unlike pralmorelin and GHRP-6, but similarly to growth hormone-releasing hormone, ipamorelin does not stimulate the secretion of adrenocorticotropic hormone or cortisol, and is highly selective for inducing the secretion only of GH.
Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus, but was discontinued due to lack of efficacy.
Ipamorelin has been used by athletes as a performance enhancing drug.
